Insider Buying: Plus Therapeutics (NASDAQ:PSTV) CFO Purchases 20,000 Shares of Stock

Plus Therapeutics, Inc. (NASDAQ:PSTV) CFO Andrew John Hugh Macintyr Sims bought 20,000 shares of Plus Therapeutics stock in a transaction dated Tuesday, November 4th. The stock was acquired at an average price of $0.51 per share, with a total value of $10,200.00. Following the acquisition, the chief financial officer directly owned 68,138 shares of the company’s stock, valued at approximately $34,750.38. This represents a 41.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Plus Therapeutics Stock Up 2.3%

Shares of PSTV traded up $0.01 during mid-day trading on Wednesday, reaching $0.52. The company’s stock had a trading volume of 1,835,229 shares, compared to its average volume of 19,981,467. The business has a fifty day moving average of $0.56 and a 200 day moving average of $0.50. The company has a market cap of $51.72 million, a price-to-earnings ratio of -0.23 and a beta of 0.81. Plus Therapeutics, Inc. has a 1 year low of $0.16 and a 1 year high of $2.31.

Plus Therapeutics (NASDAQ:PSTV) last released its earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.02). The firm had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.50 million. On average, analysts predict that Plus Therapeutics, Inc. will post -2.3 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on PSTV shares. Ascendiant Capital Markets raised their target price on Plus Therapeutics from $20.50 to $21.00 and gave the company a “buy” rating in a report on Monday, October 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Wednesday, October 8th. HC Wainwright cut their target price on Plus Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Monday. Zacks Research upgraded Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Finally, D. Boral Capital restated a “buy” rating and set a $5.00 target price on shares of Plus Therapeutics in a report on Friday, October 31st. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Plus Therapeutics presently has an average rating of “Buy” and an average target price of $7.75.

Institutional Investors Weigh In On Plus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Altium Capital Management LLC acquired a new stake in Plus Therapeutics during the third quarter worth about $628,000. Jane Street Group LLC acquired a new stake in Plus Therapeutics during the second quarter worth about $41,000. Finally, Virtu Financial LLC acquired a new stake in Plus Therapeutics during the first quarter worth about $38,000. 3.28% of the stock is owned by institutional investors and hedge funds.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.